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ABSTRACT
The phytopharmaceutical curcumin - the Indian golden spice has been widely researched for its pharmaceutical properties. It exhibits a big 
promise as a therapeutic agent due to its properties such as antioxidant, analgesic, anti-inflammatory, antiseptic activity, anticarcinogenic activity, 
chemopreventive, chemotherapeutic activity, antitumor, antiviral, antibacterial, and antifungal and is currently in human trials for a variety of 
conditions. The applications of curcumin in dentistry include its use as pit and fissure sealant, dental plaque detection system, subgingival irrigant, 
and intracanal medicament. The aim of the present paper is to review the current literature for the use of curcumin in oral mucosal lesions. A thorough 
review of the existing literature encompassing PubMed, Ovid, Embase, and Google scholar was made using the keywords curcumin, turmeric, oral, 
mucosal, oral submucous fibrosis (OSMF), oral lichen planus (OLP), aphthous, recurrent aphthous stomatitis (RAS), leukoplakia, mucositis, reverse 
smoking, tobacco-associated lesions, and premalignant. No filters in relation to language or publication year were used and only in vivo studies 
on humans were selected. Reference lists of retrieved journal articles were searched for publications missed during the primary search. Finally, 
the Google search engine was used to do a comprehensive search of the World Wide Web to ensure completeness of the search. The review of the 
literature revealed evidence of the use of curcumin in tobacco-associated conditions of the oral cavity-OSMF, oral leukoplakia, oral lesions associated 
with reverse smoking and ulcerative conditions of the oral cavity- OLP, RAS, and oral mucositis has been studied. Curcumin provides the basis for a 
simple, safe, acceptable, and cost-effective intervention for oral mucosal disorders.
Keywords: Curcumin, Oral leukoplakia reverse smoking, Oral lichen planus, Oral mucosal lesions, Oral mucositis, Oral potentially malignant disorders, 
Oral submucous fibrosis, Oral ulcers, Premalignant, Recurrent aphthous stomatitis, Recurrent aphthous, Tobacco-associated lesions, Treatment-
induced oral mucositis, Turmeric.
INTRODUCTION
In this era of herbal renaissance, the use of herbal agents in medicine 
and dentistry is gaining importance worldwide. One such nutraceutical 
is turmeric which has come all the way from the kitchen to clinic. 
Turmeric is a perennial herb of Zingiberaceae family [1]. Its botanical 
name is Curcuma longa. The rhizomes of this plant are dried and 
powdered to yield the spice turmeric. The name turmeric originates 
from the Persian word “kirkum,” meaning saffron, given due to its 
effervescent yellow-orange color [2].
Turmeric has been used in several ancient medicinal systems such as 
Ayurveda, Sidhha, Unani, and Chinese systems of medicine. Its documented 
use dates back to 6000 years [3]. The medicinal properties of turmeric 
were later discovered. Turmeric is indigenous to Southeast Asia. Indian 
contribution to the total world production of turmeric is 93.3% [3]. The 
estimated size of the Indian turmeric industry is 2500–3000 crores [4].
Several components, >100, have been isolated from turmeric. The 
major constituent of the root is a volatile oil which is composed of 
turmerone, and coloring agents called curcuminoids [5]. Curcuminoids 
include curcumin, demethoxycurcumin, 5’-methoxycurcumin, and 
dihydrocurcumin, which are natural antioxidants [6]. Curcumin, the 
principal curcuminoid, comprises approximately 2–5% of turmeric [7]. 
It owes its importance by providing the yellow color to turmeric 
and also accounts for most of its pharmacological effects. Curcumin 
possesses numerous pharmacological properties, including antioxidant, 
anti-inflammatory, antimicrobial properties, chemopreventive, and 
chemotherapeutic activity [8]. Recently, apoptosis induction effect 
of curcumin and its analogs on cancer cell lines have been shown [9]. 
A recent review has highlighted the role of curcumin as a potent 
anticarcinogenic polyphenol [10].
Several papers have reviewed the role of turmeric or curcumin in 
dentistry. The applications of curcumin in dentistry include its use as 
pit and fissure sealant, dental plaque detection system, subgingival 
irrigant, and intracanal medicament [11]. The aim of the present 
paper is to review the current literature for the use of curcumin in 
oral mucosal lesions. The antioxidant, anticarcinogenic, and anti-
inflammatory properties of curcumin make it appropriate to explore 
the role of curcumin in oral mucosal disorders. A thorough review 
of the existing literature encompassing PubMed, Ovid, Embase, and 
Google scholar was made using the keywords curcumin, turmeric, oral, 
mucosal, oral submucous fibrosis (OSMF), oral lichen planus (OLP), 
aphthous, recurrent aphthous stomatitis (RAS), leukoplakia, mucositis, 
reverse smoking, tobacco-associated lesions, and premalignant. No 
filters in relation to language or publication year were used and only 
in vivo studies on humans were selected. Reference lists of retrieved 
journal articles were searched for publications missed during the 
primary search. Finally, the Google search engine was used to do a 
comprehensive search of the World Wide Web to ensure completeness 
of the search. The review of the literature revealed evidence of the use 
of curcumin in oral mucosal lesions such as OSMF, oral leukoplakia, oral 
lesion associated with reverse smoking, RAS, OLP, and oral mucositis. 
This first half of this review will focus on the use of curcumin in 
tobacco-associated lesions such as OSMF, oral leukoplakia, and lesion 
associated with reverse smoking. Reddy et al. have also highlighted the 
role of curcumin as an anti-cancer spice in their recent review [12].
Curcumin in OSMF
Pindborg defined OSMF as “insidious chronic disease affecting any part 
of the oral cavity and sometimes the pharynx, occasionally preceded by 
vesicle formation, always associated with juxtaepithelial inflammatory 
reaction followed by a fibroelastic change of lamina propria with 
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epithelial atrophy leading to stiffness of the oral mucosa, trismus and 
inability to eat.” [13]. It is a potentially malignant disorder mainly 
caused due to areca nut chewing characterized by restricted mouth 
opening, burning sensation on having hot and spicy food, and stiffness 
and blanching of the oral mucosa. The malignant transformation rate 
of OSMF has been reported to be around 27% over several years [14].
Curcumin exhibits several properties such as anti-inflammatory, 
antioxidant and proapoptotic activities, which account for its 
chemopreventive action and is, therefore, desirable for OSMF. Curcumin 
is a dual inhibitor of arachidonic acid metabolism and, therefore, 
inhibits the products of inflammation such as prostaglandins and 
leukotrienes [15]. Curcumin also has a role in the suppression of tumor 
necrosis factor (TNF)‑induced nuclear factor‑κB (NF‑κB) activation 
and NF‑κB‑dependent reporter gene expression [16]. Downregulation 
of several products involved in cellular proliferation (cyclooxygenase 
2, cyclin D1, and c-myc), anti-apoptosis (IAP1, IAP2, XIAP, Bcl-2, 
Bcl-xL, Bfl-1/A1, TRAF1, and cellular cFLIP), and metastasis (vascular 
endothelial growth factor [VEGF], matrix metallopeptidase 9 [MMP-9], 
and intercellular adhesion molecule 1) by curcumin has been previously 
reported [17]. Rao et al. have demonstrated a very interesting effect of 
curcumin, namely the scavenging effect on superoxide radicals, hydroxyl 
radicals, and lipid peroxidation, considered a major etiopathogenetic 
factor of OSMF [18]. Recently, Zhang et al. demonstrated anti-fibrotic 
activity of curcumin in TGF‑β1‑induced myofibroblasts from human 
oral mucosa, suggesting its utility in OSMF patients [19]. It has also been 
previously demonstrated that curcumin possesses fibrinolytic action in 
liver and lung fibrosis and is regarded as a fibrinolytic agent in Chinese 
medicine [20]. Li et al. have attributed the fibrinolytic action of curcumin 
to its three properties, namely inhibition of lipid peroxidation, checking 
cellular proliferation, and inhibition of collagen synthesis [21]. Curcumin 
also suppresses bleomycin-induced pulmonary fibrosis in rats [22].
The review of the literature reveals eight research papers which have 
been published assessing the efficacy of curcumin in OSMF patients 
(Table 1). Of these four are randomized control trials (RCTs), three 
are observational studies, and one is a pre-post study design. The 
most recently published literature is an RCT by Pipalia et al. [23]. 
This study evaluated the effectiveness of turmeric with black pepper 
and Nigella sativa in OSMF patients. Tumeric with black pepper and 
N. sativa improved mouth opening, burning sensation, and superoxide 
dismutase levels in OSMF patients. The rationale behind the use of 
black pepper was it prevents the metabolism of turmeric and therefore 
increases the bioavailability of turmeric. N. sativa due to its antioxidant, 
anti-inflammatory, anticarcinogenic, immunomodulatory, and anti-
fibrotic properties was used. Furthermore, it has been tried in human 
studies for type II diabetes mellitus for glycemic control.
Hazarey et al. evaluated the efficacy of curcumin over standard medicinal 
management modality for OSMF [24]. The curcumin group was given 
Longvida lozenges (400 mg lozenges) with a total daily dose of 2 g and 
was compared to topical clobetasol propionate 0.05% to be applied 
3 times daily for 3 months. The mean decrease in the Visual analogue 
scale score and increase in mouth opening was statistically significant 
in the curcumin group as compared to the control group. The authors 
proposed that curcumin being antioxidant and anti-inflammatory may 
enhance the neoangiogenic and antifibrotic potential of the OSMF 
patients.
The observational study by Srivastava et al. investigated the clinical 
efficacy of 1 g tulsi and 1 g turmeric mixed in glycerine base for 
the treatment of OSMF patients and found statistically significant 
improvement in both burning sensation and mouth opening in the 
study population [25]. They have hypothesized that ursolic acid (UA), 
a pentacyclic triterpene acid from Ocimum sanctum (Tulsi) has been 
reported to suppress NF‑κB activation‑induced by various carcinogens. 
In addition, UA prevents proliferation and induces apoptosis and cell 
arrest in the G1-G0 phase of the cell cycle [15]. Synergistic action of 
these two herbs resulted in potent anti-OSMF treatment characterized 
by an early, sustained and significant fall in burning sensation and 
improvement in mouth opening for severe cases reflecting its higher 
efficacy.
S. No. Author(s) Type of 
evidence
n Interventions Outcomes Results
1. Pipalia et al. RCT 23 Group A received turmeric 
(400 mg) with black pepper 
(100 mg), 2 capsules TID for 
3 months. Group B received 
Nigella sativa, two capsules of 
500 mg TID for 3 months
The mouth opening and 
burning sensation were the 
primary treatment outcome 
endpoints. Cheek flexibility 
was also measured. Patients’ 
serum SOD levels were 
assessed before and after 
treatment and also compared 
with healthy controls
After the treatment Groups A and 
B showed 3.85±0.22 mm and 
3.6±0.07 mm improvement in 
mouth opening, respectively; 
87.90% and 78.91% reduction in 
burning sensation, respectively; 
and +0.62 U/ml and +0.74 U/ml 
improvement in serum SOD 
levels, respectively
2. Hazarey et al. RCT 30 Test group patients were 
treated with Longvida 
(curcumin) lozenges and 
control group with tenovate 
ointment (clobetasol 
propionate (0.05%)
IID on maximum mouth 
opening, VAS for normal food, 
and VAS for spicy food
The test group showed 5.93 
(±2.37) mm increase in mouth 
opening compared to 2.66 
(±1.76) mm of the control group. 
In relation to VAS scale with spicy 
and normal food, the average 
reduction was 64 (42–73) and 
77 (70.5–82) as compared to 34 
(14.5–64.5) and 64 (46–75.5), 
respectively in control group
3. Srivastava et al. Observational 
study
41 1 g tulsi and 1 g turmeric 
mixed 
in glycerine base applied 
3–4 times a day for 3 months
Burning sensation and mouth 
opening 
Mean burning sensation 
was 6.07±1.75 before the 
treatment and 2.22±1.41 
after the treatment (t=15.52; 
p<0.001). Mean mouth opening 
was 24.46±4.0 mm before the 
treatment and 27.85±3.39 mm 
after the treatment (t=9.06; 
p<0.001)
Table 1: Review of literature showing eight research papers assessing the efficacy of curcumin in OSMF patients
(Contd...)
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S. No. Author(s) Type of 
evidence
n Interventions Outcomes Results
4. Yadav et al. RCT 40 First group - weekly 
intralesional injection of 4 mg 
dexamethasone and 
1500 I.U hyaluronidase. 
Second group - oral 
administration of two tablets 
(turmix - tablet containing 
curcumin 300 mg and piperine 
5 mg) per day for 3 months 
each
Improvement of burning 
sensation, 
IID and TP
Improvement in burning 
sensation was from 22.4 (8.7) to 
15.6 (11.2) in Group 1 compared 
to 63.5 (24.7) to 0 in curcumin 
group. The mean increase in IID 
was 3.13 and 1.25 mm. Mean 
increase in TP was 2.56 mm 
and 0.38 mm in Groups 1 and 2, 
respectively
5. Agarwal et al. Observational 
study
30 Turmix (tablet containing 
curcumin 300 mg and piperine 
5 mg) TDS for 1 month
Patient’s mouth opening and 
burning 
sensation on VAS
The change in burning sensation 
on VAS scale was statistically 
significant, and maximum 
improvement was observed in 
Group B (83.33%). The overall 
change in mouth opening 
was 0.69 cm which was not 
statistically significant, with 
maximum improvement in late 
stages (Group D)
6. Das et al. RCT 48 Group I patients was given 
curcumin capsules, Group II 
TO, and Group III the control 
group was provided with 
multinal tablets for 3 months
Improvement of burning 
sensation, 
IID, and TP and H/P
Significant improvement was 
observed in the clinical signs and 
symptoms of patients treated 
with curcumin and TO when 
compared to those with multinal
7. Rai et al. Pre-post study 25 
(100)
Curcumin 1 g caplets 
(900 mg curcumin and 80 
mg desmethoxycurcumin, 
and 20 mg 
bisdesmethoxycurcumin) 
Pain control using VAS and 
lesion healing measured by 
lesion size and mouth opening 
salivary and serum oxidative 
markers such as MDA, 8-OHdG, 
and Vitamins C and E were 
analyzed at baseline, 1 week 
and after clinical cure of the 
lesion
Salivary MDA levels decreased 
from 0.32 (0.16)–0.11 and 
serum levels decrease from 
1.19 (0.37)–0.98 (0.67). Levels 
of 8-OhdG showed a similar 
decrease in salivary (0.32–0.11) 
and serum samples (2.12–1.89). 
Levels of Vitamin C increased in 
salivary samples (1.01–1.45) as 
well as in serum (8.56–9.05. A 
similar trend was observed in 
Vitamin E in salivary (0.67–0.89) 
and serum samples (8.08–8.97). 
Mouth opening increased from 
24.64 (3.2) to 39.4 (3) mm 
(p<0.05)
8. Hastak et al. Observational 
study 
90 Group 1: 15 patients received 
a total of 3 g/day of TE 
in three equal doses; 10 
patients completed 3 months 
treatment and served as 
positive controls; Group 2: 22 
patients were given 600 mg 
TOR per day mixed in 3 g 
of TE in three equal doses; 
13 patients continued up to 
3 months; and Group 3: 21 
patients were given 600 mg 
TO per day mixed with 3 g 
of TE; 16 patients continued 
up to 3 months. 32 normal 
healthy subjects without 
chewing and smoking habits 
and of comparable age were 
studied for comparison with 
the treatment groups
Number of micronucleated 
cells in exfoliated oral 
mucosal cells and circulating 
lymphocytes
Number of micronuclei/100 
cells in exfoliated buccal 
mucosal cells in normal 
patients was 2.2±0.17 and 
10.2±0.28 in OSMF patients. 
This decreased to 3.9±0.23 in 
patients of Group 1, 3.8±0.23 
in patients of Group 2, and 
2.7±0.22 in patients of Group 3. 
A similar trend was observed 
in micronuclei/100 cells in 
circulating lymphocytes
OSMF: Oral submucous fibrosis, SOD: Superoxide dismutase, VAS: Visual analogue scale, IID: Interincisal distance, TP: Tongue protrusion, 8-OHdG: 8-hydroxydeoxyguanosine, 
MDA: Malondialdehyde, TOR: Turmeric oleoresin, RCT: Randomized control trial, TO: Turmeric oil
Table 1: (Continued)
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In the study by Yadav et al., complete, rapid, and early improvement of 
burning sensation was observed with curcumin compared to a mean 
15.6% residual burning sensation at the end of therapy in the steroid 
group [26]. Improvement in mouth opening and tongue protrusion was 
less as compared to intralesional steroids. The authors recommended 
that early use of curcumin in OSMF patients provides rapid symptomatic 
relief and, therefore, is beneficial and effective in the management of 
early OSMF. Similar results have been obtained by Srivastava et al. who 
reported significant improvement in burning sensation only, not mouth 
opening, in OSMF patients following treatment with curcumin [25]. In 
their study, maximum improvement in mouth opening was observed in 
the late stage while maximum improvement in burning sensation was 
observed in early stages.
The study by Das et al. compared curcumin, turmeric oil (TO), and 
multinal tablets and found that curcumin produced a quicker reduction 
in burning sensation and intolerance to spicy food, though TO was 
found to have a long-term effect on follow-up evaluation [27]. Complete 
relief of pain was reported with both curcumin and TO, while pain 
persisted in 5 patients in the multinal group. Statistically significant 
and equal increase in mouth opening of patients in Groups I and II was 
observed. The remarkable reduction in clinical scoring after 15 days 
of treatment with curcumin and TO was observed and was confirmed 
histopathologically as well. They also reported that curcumin and TO 
were well-tolerated without adverse events.
The study by Rai et al. studied 25 patients each of OSMF, oral 
leukoplakia, and OLP and 25 controls and assessed oxidative stress 
markers in serum and saliva [28]. The mean and median values of 
serum and salivary Vitamins C and E showed an increase, while 
malondialdehyde (MDA) and 8-hydroxydeoxyguanosine (8-OHdG) 
levels showed decreases in OSMF patients 1 week after intake of 
curcumin. These values were statistically significant after curing of 
OSMF in an average of 211 (17) days. A similar trend of increase in 
Vitamins C and E levels and a decrease of MDA and 8-OHdG levels were 
observed when the comparison of OSMF patients with healthy controls 
was made, at baseline and after 209 days. Improvement in pain scores, 
size of the lesion, and mouth opening was also significant. This research 
suggested that curcumin significantly increases the local and systemic 
antioxidant status and the levels of Vitamins C and E, while it decreases 
the lipid peroxidation and DNA damage of patients with potentially 
malignant disorders. Curcumin quenches reactive oxygen species (ROS) 
production at low concentrations and induces ROS production at high 
concentration.
Hastak et al. did a combination of in vitro and in vivo study in OSMF 
patients and showed that there is increased the incidence of micronuclei 
(Mn) in exfoliated oral mucosal cells and circulating lymphocytes of 
patients suffering from OSMF [29]. In this study, the authors report non-
mutagenicity of TO and turmeric oleoresin (TOR) on the basis of the 
fact that TO and TOR did not induce an increase in Mn in lymphocytes 
when treated individually. They also report the chemoprotective effect 
of TO and TOR in lymphocytes of normal healthy subjects in vitro and 
recovery from DNA damage in OSMF patients in vivo.
Curcumin in oral leukoplakia
According to the World Health Organization (WHO) workshop 
consensus “the term leukoplakia should be used to recognize white 
plaques of questionable risk having excluded (other) known diseases 
or disorders that carry no risk for cancer” [30]. Oral leukoplakia is the 
most commonly encountered oral potentially malignant disorder and 
presents as homogenous form and non-homogeneous forms [31].
Curcumin suppresses mutagenesis and has been used as a 
chemopreventive agent in a variety of cancers including those arising in 
the oral cavity [32]. Several mechanisms are involved in the prevention 
of carcinogenesis by curcumin. It involves upregulation of carcinogen-
detoxifying enzymes such as glutathione S-transferases [33,34] 
antioxidation [35,36], and suppression of expression of the isoenzyme 
cyclooxygenase-2 [37,38]. It shows greater modulation of translational 
mechanism in immortalized normal, premalignant, and malignant cells 
as compared to normal cells [39].
Review of existing literature shows that apart from the study by 
Rai et al. [28] which also included 25 oral leukoplakia patients, two 
other reports have studied the effect of curcumin on oral leukoplakia 
(Table 2).
A prospective phase-I study was conducted to evaluate the biologically 
effective dose of curcumin in humans and study the toxicology 
and pharmacokinetics of curcumin [40]. Patients with five high-
risk conditions, namely recently resected urinary bladder cancer, 
arsenic Bowen’s disease of the skin, uterine cervical intraepithelial 
neoplasm, oral leukoplakia, and intestinal metaplasia of the stomach, 
were recruited. Curcumin was administered orally in 25 patients for 
3 months at a starting dose of 500 mg/day. The dose was escalated to a 
higher level up to 12,000 mg/day if no toxicity ≥Grade II was noted in 
at least three successive patients. Results after 3 months showed the 
histological improvement of precancerous lesions in 1 of 2 patients with 
recently resected bladder cancer, 2 of 7 patients of oral leukoplakia, 1 
of 6 patients of intestinal metaplasia of the stomach, 1 of 4 patients 
with contrast-induced nephropathy (CIN), and 2 of 6 patients with 
Bowen’s disease suggesting role of curcumin in chemoprevention. One 
patient with CIN and another with oral leukoplakia developed frank 
malignancies even after receiving curcumin treatment. No treatment-
related toxicity up to the dose of 8000 mg/day was reported. The bulky 
volume of the drug was a deterrent to the patients on giving higher 
dosage.
In an intervention study from Sri Lanka, 72 betel quid chewers with 
oral potentially malignant lesions were randomly divided into two 
groups and were given either curcumin-coated chewing gum or 
placebo chewing gum [41]. The patients were followed every month 
while the sizes of lesions were measured every 6 months. The results 
showed that oral potentially malignant lesions of the curcumin group 
were significantly smaller within 6 months (p<0.05) and quitting betel 
quid chewing, and the use of curcumin had synergistic effects on the 
reduction of the lesion size.
Curcumin in treating palatal changes associated with reverse 
smoking
The term “palatal changes” describes the reaction of the palatal mucosa 
to reverse chutta smoking, a form of smoking more prevalent among 
females of Andhra Pradesh [42]. It encompasses several entities such 
as palatal keratosis, excrescences, altered pigmentation, erythematous 
areas, white or mixed red and white patches, and palatal ulcers. 
The study by Vijayalaxmi et al. evaluates the efficacy of curcumin 
preparation on the palatal changes associated with reverse smoking 
in 20 patients [43]. The study group was advised to use curcumin oral 
gel on an acrylic palatal plate along with instructions to quit smoking 
whereas control group patients were instructed about the benefits of 
smoking cessation only. Clinical and cytological smear examinations 
were performed for three visits at 15 days interval. Clinical improvement 
was graded as mild (¼ reduction in the clinical presentation), moderate 
(½ reduction in the clinical presentation), and fully improved if there 
was no evidence of the clinical lesion or no improvement if the lesion 
was persisting as it was. Evident improvement with reduction in size 
and severity of the clinical lesion was observed among the study group 
at both the first and third visits. However, the cytological appearances 
remained the same in all the cases, except for three cases from the study 
group, which demonstrated a transition from moderate dysplastic 
features to milder dysplastic features.
Curcumin on OLP
OLP is an immunologically mediated mucocutaneous disorder. Lichen 
planus affects the skin, oral mucosa, nail, genital mucosa, and scalp [44]. 
Skin lesions are classically described as purple, pruritic, and polygonal 
papules usually affecting the flexor surface of extremities [45]. Oral 
36
Asian J Pharm Clin Res, Vol 12, Issue 2, 2019, 32-43
 Rai et al. 
lesions can present as reticular, erosive, atrophic, plaque-like, popular, 
or bullous type [46]. Reticular lichen planus is associated with better 
prognosis [47]. The occurrence and distribution of lesion in the oral 
mucosa are 80% in the buccal mucosa, 65% in the tongue, 20% lips, 
and <10% seen in the floor of mouth and palate [48]. The follow-up 
studies of OLP reveal the malignant transformation of this condition to 
be up to 5.3% [49].
The review of the literature reveals five research papers which have 
been published assessing the efficacy of curcumin in OLP patients 
(Table 3). Of these, three have been authored by Chainani-Wu et al. [50]. 
First was a phase-II randomized, double-blind, and placebo-controlled 
trial evaluating the efficacy and safety of curcuminoids as an adjunct 
to short-course corticosteroids for the treatment of patients with 
atrophic or erosive OLP. The trial was conducted between February 
2003 and September 2004, curcuminoids at 2000 mg/day for 7 weeks 
and prednisone at 60 mg/day for the first 1 week were given. The first 
interim analysis conducted in October 2004 using data from the first 33 
subjects did not show a significant difference between the placebo and 
curcuminoids groups. Therefore, the study was ended early for futility. 
The initial course of prednisone was used in this trial due to ethical 
concerns regarding a placebo-controlled trial extending for 7 weeks 
among patients with significant oral discomfort. It was concluded 
that an RCT of a shorter duration, using a higher dose of curcuminoids 
without an initial course of prednisone, should be considered.
As a next step, randomized, double-blind, and placebo-controlled 
clinical trial were conducted in 2007 through 2008 with 20 patients 
of OLP [51]. Curcuminoids at doses of 6000 mg/day (3 divided doses) 
were given, and the curcuminoids group showed a greater reduction 
in clinical signs and symptoms as compared with the placebo group. 
Although the small sample size resulted in the limited power of the 
study, curcuminoids at doses of 6000 mg/day in 3 divided doses are 
well-tolerated.
In their third paper, the authors summarized the long-term open-
label use of curcuminoids and experience of side effects (SEs) in 
53 patients with OLP who had previously participated in RCTs of 
curcuminoids [52]. Of the 53 eligible patients, data were available for 
44 (25/33) (75%) from the first and 19/20 (95%) from the second 
RCT. 18/25 participants from the first trial and 19/19 from the second 
trial took over-the-counter curcuminoids after completion of the trial 
period. The mean total daily dose was 2137.5 mg for 18/25 patients 
and 5058 mg for the 19/19 patient group. 10/18 (56%) reported that 
Table 2: Review of literature showing three research papers assessing the efficacy of curcumin in oral leukoplakia patients
S. No. Author(s) Type of evidence n Interventions Outcomes Results
1. Cheng et al. Phase I clinical 
trial 
25 (7) The starting dose was 
500 mg/day for 3 months. 
If no toxicity ≥Grade II 
was noted in at least three 
successive patients, the 
dose was then escalated to 
another level in the order 
of 1000, 2000, 4000, 8000, 
and 12,000 mg/day 
The concentration of 
curcumin in serum and 
urine was determined 
by high-pressure liquid 
chromatography. 
Biopsy of the lesion sites 
was done immediately 
before and 3 months 
after starting curcumin 
treatment
The average peak serum 
concentrations after taking 
4000 mg, 6000 mg, and 
8000 mg of curcumin were 
0.51±0.11 µM, 0.63±0.06 µM, 
and 1.77±1.87 µM, 
respectively. Urinary excretion 
of curcumin was undetectable. 
1 of 4 patients with CIN and 
1 of 7 patients with oral 
leukoplakia proceeded to 
develop frank malignancies in 
spite of curcumin treatment. 
Histologic improvement of 
precancerous lesions was 
seen in 2 of 7 patients of oral 
leukoplakia
2. Chiba et al. RCT 72 Curcumin-coated chewing 
gum and placebo chewing 
gum 
The sizes of lesions 
were measured every 
6 months
The oral precancerous lesions 
of the curcumin group were 
significantly smaller within 
6 months (p<0.05). Quitting 
betel quid chewing and the use 
of curcumin had synergistic 
effects on the reduction of the 
lesion size (p<0.05)
3. Rai et al. Pre-post study 25 (100) Curcumin 1 g caplets 
(900 mg curcumin, 80 mg 
desmethoxycurcumin, 
and 20 mg 
bisdesmethoxycurcumin) 
Pain control using VAS 
and lesion healing 
measured by lesion size 
and mouth opening 
salivary and serum 
oxidative markers such 
as MDA, 8-OHdG, and 
Vitamins C and E were 
analyzed at baseline, 1 
week and after clinical 
cure of the lesion
Salivary MDA levels decreased 
from 0.32 (0.16) to 0.11 and 
serum levels decrease from 
1.19 (0.37) to 0.98 (0.67). 
Levels of 8-OhdG showed a 
similar decrease in salivary 
(0.32–0.11) and serum samples 
(2.12–1.89). Levels of Vitamin 
C increased in salivary samples 
(1.01–1.45) as well as in serum 
(8.56–9.05). A similar trend 
was observed in Vitamin E in 
salivary (0.67–0.89) and serum 
samples (8.08–8.97). Mouth 
opening increased from 24.64 
(3.2) to 39.4 (3) mm (p<0.05)
CIN: Contrast-induced nephropathy, MDA: Malondialdehyde, 8-OHdG: 8-hydroxydeoxyguanosine, RCT: Randomized control trial
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S. No. Author(s) Type of 
evidence
n Interventions Outcomes Results
1. Chainani-
Wua et al.
RCT 100 Study subjects were 
randomized to receive 
either placebo or 
curcuminoids at 
2000 mg/day for 7 weeks. 
In addition, all subjects 
received prednisone at 
60 mg/day for the first 1 
week
The primary outcome 
was a change in symptom 
score from the baseline 
to the last follow-up visit 
at week 7. Secondary 
endpoints included 
changes in symptom 
scores from baseline 
at weeks 1 and 4, and 
changes in clinical signs 
from baseline at weeks 
1, 4, and 7, as well as the 
occurrence of adverse 
effects. Five assessments 
- VAS, NRS, CSS, MOMI, 
and SEs (10-item 
questionnaire) were at 0, 
1, 4, and 7 weeks
The first interim analysis 
(33 patients) did not show 
a significant difference 
between the placebo and 
curcuminoids groups. The 
changes in NRS values from 
baseline to 7 weeks in the 
placebo and curcuminoids 
groups were −1.996 and 
−1.666, respectively; changes 
in VAS values were −19.743 
and −15.476, respectively; and 
changes 




RCT 20 Study subjects were 
randomized to receive 




symptoms and signs of 
OLP using NRS and MOMI, 
CBC, liver enzymes; 
C-reactive protein; and 
IL-6 levels were done at 
baseline and day 14
In the placebo group, the 
percentage changes from 
baseline in NRS (median 
[interquartile range] =0.00 
[−29–16.7], p>0.99), erythema 
(0.00 [−10–16.7], p=0.98), 
ulceration (0.00 [0.00–26.7], 
p=0.63), and total MOMI 
scores (−3.2 [−13–9.09], 
p=0.95) were not statistically 
significant, whereas they were 
statistically significant in the 
curcuminoids group: NRS 
(−22 [−33–−14], p=0.0078); 
erythema (−17 [−29–−8.3], 
p=0.0078), ulceration (−14 
[−60–0.00], p=0.063), and 
MOMI (−24 [−38–−11], 
p=.0039). The curcuminoids 
group showed a greater 
reduction in clinical signs and 
symptoms as compared with 
the placebo group, measured 
by percentage change in 
erythema (p=0.05) and 
total MOMI score (p=0.03), 
and proportion showing 
improvement in NRS (0.8 
vs. 0.3, p=0.02) and total 
MOMI score (0.9 vs. 0.5, 
p=0.05). Adverse effects were 












Collected information from 
clinic charts and patient 
interview on the OTC use of 
curcuminoids during a 1–5-
year follow-up period
18/25 (72%) participants 
from the first trial - mean 
total daily dose was 
2137.5 mg (SD=793, 
range 500–3000 mg) and 
mean duration of use was 
30 months (SD=27.5). 
19/19 (100%) patients 
from the second trial - 
mean total daily dose was 
5058 mg (SD=1445, range 
1000–6000 mg) and 
mean duration was 9.6 
months (SD=8.04)
10/18 (56%) reported that 
curcuminoids 
controlled OLP symptoms, 
mean duration - 35.8 months 
(SD=27.4). 8/18 (44%) - 
unsure, mean duration of use 
was 21.0 months (SD=27.3). 
2/18 patients (11%) reported 
a SE of diarrhea
Table 3: Review of literature showing five research papers assessing the efficacy of curcumin in OLP patients
(Contd...)
38
Asian J Pharm Clin Res, Vol 12, Issue 2, 2019, 32-43
 Rai et al. 
S. No. Author(s) Type of 
evidence
n Interventions Outcomes Results
4. Rai et al. Pre-post 
study
25 (100) Curcumin 1 g caplets 
(900 mg curcumin, 80 mg 
desmethoxycurcumin, 
and 20 mg 
bisdesmethoxycurcumin)
Pain control using VAS 
and lesion healing 
measured by lesion size 
and mouth opening 
salivary and serum 
oxidative markers such 
as MDA, 8-OHdG, and 
Vitamins C and E, were 
analyzed at baseline, 
1 week and after clinical 
cure of the lesion
Salivary MDA levels decreased 
from 0.32 (0.16) to 0.11 
and serum levels decrease 
from 1.19 (0.37) to 0.98 
(0.67). Levels of 8-OhdG 
showed a similar decrease 
in salivary (0.32–0.11) and 
serum samples (2.12–1.89). 
Levels of Vitamin C increased 
in salivary samples (1.01–
1.45) as well as in serum 
(8.56–9.05). A similar trend 
was observed in Vitamin E 
in salivary (0.67–0.89) and 
serum samples (8.08–8.97). 
Mouth opening increased 
from 24.64 (3.2) to 
39.4 (3) mm (p<0.05)
5. Singh et al. Pilot study 10 Extract of turmeric in the 
ointment form was made 
at NBRI, used for local 
application twice/day for a 
period of 3 months
Reduction in sign score 
(Thongprasom), pain 
score (VAS) lesion before 
and after treatment
Sign score was 5 in 8 patients 
and 4 in 2 patients initially 
which changed to score 0 in 
9 patients and 1 in 1 patient. 
Initially, pain on VAS for all 10 
patients was between 2 and 4 
which changed to 0–2 after the 
treatment
RCT: Randomized control trial, CSS: Change in symptoms scale, MOMI: Modified oral mucositis index, OLP: Oral lichen planus, VAS: Visual analogue scale, CBC: Complete 
blood count, IL-6: Interleukin-6, NRS: Numeric rating scale, OTC: Over-the-counter, SD: Standard deviation, SE: Side effect
Table 3: (Continued)
curcuminoids controlled OLP symptoms, and the mean duration of use 
among these patients was 35.8 months. 12/19 (63%) reported that 
curcuminoids controlled OLP symptoms, and the mean duration of use 
was 14.1 months. It was concluded that total of 22/37 (60%) of patients 
reported a reduction of symptoms with curcuminoids, 13/37 (35%) 
were unsure and 2/37 (5%) reported that it did not help in reduction of 
symptoms. SEs included abdominal discomfort and diarrhea; however, 
the occurrence was dose-related, and complaints were mild.
Rai et al. [28] studied 25 patients each of OSMF, oral leukoplakia, and 
OLP, and 25 controls and proved that anti-precancerous effects of 
curcumin are mediated through prooxidant and antioxidant pathways.
In a pilot study, topical application of curcuminoids was studied on 
10 patients of OLP [53]. The extract of turmeric in the ointment form 
was used for local application twice/day for a period of 3 months. 
Significant improvement was noted in the signs and symptoms in 
the follow-up period. It was suggested that curcumin has an immune 
modulatory effect which could prove beneficial in the management of 
this cell-mediated autoimmune disorder.
Curcumin in RAS
RAS is a common condition characterized by the presence of recurring 
oval or round ulcerative lesions affecting oral mucosa [54]. Multifactorial 
etiology has been proposed involving various predisposing factors such 
as stress, trauma, food, hormonal imbalance, nutritional deficiency, 
and smoking [55]. RAS has been classified by Stanley in three 
variants - minor RAS, major RAS, and herpetiform ulceration [56].
The possible mechanism of action of the curcumin in RAS involves 
the decreased rate of release and metabolism of arachidonic acid, 
leading to diminished activities of phospholipase A2, cyclooxygenase, 
and lipoxygenase [57]. Previous studies show that curcumin could 
downregulate the expression of cytokines such as interleukin (IL)-6, 
TNF‑α, and various other chemokines. Thus, curcumin suppresses 
inflammation through multiple pathways [58]. Animal studies 
have shown that oral administration of curcumin in instances of 
acute inflammation was found to be equally effective as cortisone 
or phenylbutazone and half as effective in cases of chronic 
inflammation [59]. The activity of curcumin in acute ulcer model in 
rats has been studied [60]. It causes re-epithelization and accelerated 
the healing process and protected gastric ulcer through attenuation of 
MMP-9 activity and amelioration of MMP-2 activity. In an animal study, 
curcumin increased cellular proliferation and collagen synthesis at the 
wound site [61]. An immunohistochemical study evaluating the impact 
of curcumin on oral ulcer healing in rats proved that administration 
of curcumin in normal rats with tongue ulcer leads to increased 
expression of TGF‑β and increased expression of α SMA associated with 
increased migration of epithelial cells, which lead to smaller ulcer size 
in the first 9 days [62]. Thorat et al. have formulated a thermoreversible 
mucoadhesive gel containing curcumin for the treatment of mouth 
ulcer and characterized it [63].
A literature search for use of curcumin in RAS patients revealed five 
trials, of which four are RCT, and one is a controlled study (Table 4).
Deshmukh et al. [64] compared the efficacy of curcumin with 
triamcinolone acetonide in the gel form in the treatment of minor RAS. 
Their study showed that there was a significant difference between 
the pain score, size, number, and duration of ulcers from day 0 to day 
7 in both the groups, respectively. Statistical significance was not noted 
between all the parameters when both the groups were compared 
with each other. The results of this study provide positive evidence 
that curcumin gel can be used as an effective and safer alternative to 
steroids in the treatment of minor RAS. A similar study comparing 
turmeric and triamcinolone was conducted by Halim et al. [65]. There 
were significant differences in the pain score and ulcer size on days 1 
and 5 in both the groups, but there is no significant difference between 
turmeric and triamcinolone for the treatment of minor RAS. Even 
though the differences were not significant, for mean comparison, the 
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S. No. Author(s) Type of 
evidence
n Interventions Outcomes Results
1. Deshmukh et al. RCT 60 Group I - Curcumin gel group 
(10 mg of C. longa extract/g) and 
Group II - triamcinolone 
acetonide (0.1%) gel group 
patients in either group were 
asked to apply the gel 3 times a 
day on each ulcer
Ulcer size measured 
along its longest 
diameter, number of 
ulcers, duration of 
healing, and pain score 
was 0–10 using the VAS 
on day 0, 3, 5, and 7
Reduction in pain (4.7±1.53 
in Group I and 4.5±1.43 in 
Group II), size 
(−3.8±1.08 in Group I and 
−3.7±1.53 in Group II), and 
the number of ulcers 
(−1.2±0.38 in Group I and 
−1.5±0.77 in Group II) and 
duration of ulcers 
(3.9±1.18 in Group I and 
4.1±1.18 in Group II) was 
statistically significant in 
both the groups from day 0 
to day 7, respectively; but 
on the comparison between 
Groups I and II, no statistical 
significance was noted
2. Halim et al. RCT 20 Group I received turmeric 
powder, and Group II received 
triamcinolone acetonide, to be 
applied for 5 min twice per day
The VAS has been used 
to assess the pain score, 
and the ulcer size was 
measured by sliding 
caliper on day 1 and 5
The statistically significant 
difference in reduction in pain 
score from day 1 (4.40±1.713) 
to 5 (0.80 ±2.530) in 
Group II and the Group I 
(5.7±1.767 day 1; 1.1±1.287 
day 5) was observed. A 
similar difference in size 
of the ulcer for the Group I 
(mean 23.7042±82.05465) 
and Group II (mean 
51.4677±60.71060) were 
observed. No significant 
difference between turmeric 
and triamcinolone for the 
treatment of minor recurrent 
aphthous ulcer observed
3. Manifer et al. RCT 57 Group I received placebo gel, and 
Group II received curcumin gel 
2%, to be applied twice per day
Size of ulcers 
measured by the 
investigator, pain 
evaluated based on 
perceived 
pain rating scale before 
drug application (day 
0) and at days 4, 7, and 
14 as well as subject 
overall satisfaction score 
at the end of 
treatment on four-




Mean ulcer pain of 
two groups matched well at 
baseline but was significantly 
relieved in the turmeric group 
at day 4 (p<0.05). Ulcer size 
of the treatment group and 
the placebo group matched 
well at 
the study entry (p>0.05), 
significant group differences 
appeared at the later visits 
(days 4 and 7; p<0.05). Highly 
significant group differences 
appeared at 
the end of the trial regarding 






20 Group I - antiseptic gel topically 
twice daily. Group II - instructed 
to hold 2.5 ml of curcumin oil 
(1 ml of curcumin oil contained 
250 mg curcumin) mixed with 
10 ml of milk for 1–2 min and 
spit, twice daily
The number of ulcers, 
the intensity of pain, the 
period of healing and 
frequency of recurrence 
through log diaries given 
to the patient. Pain was 
assessed using 
VAS
Patients who used curcumin 
oil reported that ulcers 
started healing earlier than 
in previous attacks; there 
was also an early reduction 
in pain. A follow up for 1 year 
has shown no recurrence in 
these patients
Table 4: Review of literature showing five research papers assessing the efficacy of curcumin in recurrent aphthous ulcer patients
(Contd...)
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triamcinolone had a greater value of mean for ulcer size, indicating 
turmeric was better in reducing the size of the ulcer. Similarly, for pain 
score, turmeric was the better medicament for relieving the pain of the 
ulcer compared to triamcinolone.
In a randomized, double-blind, and placebo-controlled trial of patients 
with minor RAS efficacy of curcumin gel containing 2%, curcumin was 
studied [66]. Curcumin gel significantly reduced pain intensity and size 
of aphthous ulcer compared to placebo. Significant group differences 
were also observed at the end of the trial regarding overall satisfaction 
of the patients. A study focusing on the therapeutic effects of curcumin 
in RAS in comparison to conventional antiseptic gel found that curcumin 
could produce a remarkable reduction in recurrence of RAS (follow-up 
for 1 year) [67]. In addition, ulcers treated with curcumin healed faster 
and were associated with early relief in pain.
Al-Saffar [68] studied the efficacy of two different concentrations of 
the viscous curcumin solution on the healing of ulcer in patients with 
RAS and compared it with a positive and negative control. Complete 
recovery occurred from 5 days (73% patients in curcumin solution 10% 
and 78.7% in curcumin solution 50%) to 11 days (6.6% in curcumin 
solution 10% and 3.2% in curcumin solution 50%). However, in control 
negative group (without treatment), the complete recovery occurred 
from 5 days (20%) to 11 days (40%) only. In control positive group 
(received glycerin vehicle treatment), the complete recovery occurred 
from 5 days (30%) to 11 days (20%).
Curcumin in oral mucositis
Oral mucositis refers to erythematous and ulcerative lesions of the 
oral mucosa observed in patients treated with chemotherapy, and/or 
with radiation therapy to fields involving the oral cavity. Lesions of oral 
mucositis are extremely painful and compromise nutrition and oral 
hygiene, thereby increase the risk for local and systemic infection [69]. 
Fractionated radiation dosage increases the risk of mucositis to >70% 
of patients in most trials [70].
The pathophysiology of mucositis is multifarious and involves 
direct cellular effects brought about by DNA damage and generation 
of ROS. Amplification of signaling pathways, for example, TNF-α 
release, NF-κB activation, and ROS potentiates cell death, mediating 
mucosal damage. Polymicrobial flora in the oral cavity potentiates 
proinflammatory cytokine release [71]. Curcumin offers potential 
preventive and therapeutic benefit in oral mucositis due to its anti-
inflammatory and antibacterial properties. Lüer et al. [72] assessed 
the in vitro extent of bactericidal activity of curcumin on pharyngeal 
cells. Complete suppression of the release of TNF‑α, IL‑6, IL‑8, 
monocyte chemoattractant protein 1, granulocyte macrophage-colony 
stimulating factor, and VEGF was observed. Repetitive exposure to 
curcumin resulted in repetitive suppression of cytokine/chemokine 
expression lasting from 4 to 6 h. Therefore, the authors concluded that 
through reduction of oral microbial concentration and suppression of 
inflammation cascades, curcumin may play a role in oral mucositis.
Review of literature revealed four studies evaluating the role of 
curcumin in treatment and prevention of oral mucositis (Table 5).
Patil et al. [73] evaluated the efficacy and safety of curcumin mouthwash 
in comparison with chlorhexidine in the management of oral mucositis. 
Curcumin was found to be better than chlorhexidine mouthwash in 
terms of rapid wound healing and better patient compliance. No oral or 
systemic complications were reported in this study.
Saldanha and Almeida [74] compared turmeric and saline mouthwash 
on oral mucositis. There was a significant difference in the score of 
oral mucositis between pre-intervention on day 1 morning and post-
intervention score on day 5 evening in both turmeric and saline group 
but on comparison it was found that turmeric mouthwash was more 
effective than saline mouthwash in all the days except in day 3 where 
there was no significant difference found.
Elad et al. [75] undertook a pilot study to assess the tolerability of a 
curcumin mouthwash for the management of oral mucositis. They had 
originally designed a placebo-controlled study, but gastrointestinal 
adverse events (nausea and vomiting) affected the compliance of the 
first three participants who were receiving placebo. Due to ethical 
issues, the control group was discontinued and the authors reported 
their results as a case series. In this study, the authors suggested that 
curcumin mouthwash was safe and well-tolerated.
S. No. Author(s) Type of 
evidence
n Interventions Outcomes Results
5. Al-Saffar RCT 83 Group A: 30 patients received 
a viscous solution of curcumin 
10%; Group B: 33 patients 
received a viscous solution of 
curcumin 50%; Group C: 10 
patients without treatment 
(control negative); and Group 
D: 10 patients received glycerin 
treatment (control positive)
Healing time and 
symptomatic relief of 
individual treatment. 
Appearance of lesion, 
zone of inflammation and 
pain was recorded at each 
visit during the 
healing phase
There was a significant 
difference in the percentage 
of complete healing between 
control negative group and 
groups of patients using a 
viscous solution of curcumin 
10% and 50% (p<0.05), 
and there was a significant 
difference in the percentage of 
complete 
healing between control 
positive group, groups of 
patients using a viscous 
solution of curcumin 10% and 
those using 
viscous solution of curcumin 
50% (p<0.05). While there is 
no significant difference 
between groups of patients 
using a viscous solution of 
curcumin 10% of those using 
a viscous solution of curcumin 
50% (p>0.05)
RCT: Randomized control trial, VAS: Visual analogue scale, C. longa: Curcuma longa
Table 4: (Continued)
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Table 5: Review of literature showing four research papers assessing the efficacy of curcumin in oral mucositis patients
S. No. Author(s) Type of 
evidence
n Interventions Outcomes Results














each to be used 
thrice daily
The WHO scale, the OMAS, 
and NRS (NRS; patient 
reporting scale of 0–10) 
were used for assessment at 
days 0, 10, and 20. Adverse 
events were tracked
On the comparison between 
the baseline and 2nd follow-up 
scores of the study and control 
groups, NRS (p<0.001), erythema 
(p=0.050), ulceration (p<0.001), 
and WHO (p=0.003) were found 
to be statistically significant


















mixing 1.5 g of 
turmeric powder 
with 50 ml of 
water). Group II 
received saline 
mouth, 3 times/
day for 5 days
Oral mucositis assessment 
checklist and pain using pain 
scale every morning 
before the intervention 
and evening after the 
intervention
The mean pre-test TIOM score 
of Group I was 25.35 whereas 
in post-test it is 18.85. The 
mean of pre-test TIOM score of 
Group II was 25.05 whereas in 
post-test it is 20.15. The mean 
post-interventional scores (day 5 
evening) in Groups I and II were 
significantly lower than the mean 
pre-interventional scores (day 1 
morning) In comparison, it was 
found that turmeric mouthwash 
was effective than a saline mouth 
in all the days except in day 3 
where there was no significant 
difference found
3. Elad et al. Pilot 
study







10 drops of 
curcumall in a 
half glass (50 ml) 












with high dose 
chemotherapy
The primary outcome 
measure was oral adverse 
events related to curcumin 
use, and secondary 
outcome measures were 
OMAS, WHO 
mucositis scale, and VAS. OM 
was assessed on days 0, 7, 
10, 14, and 21 days
No oral or systemic adverse 
events were documented. In the 
four patients who fulfilled the 
compliance criteria, the WHO, 
OMAS, and VAS scores were 
lower than the severity of oral 
mucositis previously reported 
in the literature. 4 of the 5 
participants developed OM, but 
the values were low, reflecting a 
relatively mild case. Duration of 
neutropenia ranged from 3 to 8 
days, with an average of 4. Opioid 
use ranged from 0 to 4 days with 
an average of 1.5 days. Moreover, 
finally, hospitalization ranged 
for all subjects between 0 and 
12 days with a median of 7. No 
parenteral nutrition was required
4. Rao et al. RCT 80 head and neck 
cancer patients 
requiring 70 Gy 
of radiation or 
chemoradiotherapy










Oral mucositis was assessed 
using the RTOG grading 
system before the start, 
during, and at the end of the 
treatment by an investigator 
unaware of the treatment. 
The primary endpoint of this 
study was the incidence of 
mucositis every week during 
the 7-week period. The 
secondary endpoint was the 
effect of turmeric gargle on 
the incidence of treatment 
breaks, loss of scheduled 
treatment days, and a 
decrease in body weight at 
the end of the treatment
Compared with the cohorts using 
povidone-iodine gargle, the group 
using turmeric as a mouthwash 
had delayed and reduced the 
levels of radiation-induced oral 
mucositis and was statistically 
significant at all-time points 
(p<0.001–p<0.0001). In addition, 
the cohorts using turmeric had 
decreased intolerable mucositis 
(p<0.001) and lesser incidence of 
the treatment breaks in the first 
half of the treatment schedule 
before 4 weeks (p<0.01) and 
reduced change in body weight 
(p<0.001)
NRS: Numeric rating scale, WHO: World Health Organization, OMAS: Oral mucositis assessment scale, TIOM: Treatment-induced oral mucositis, VAS: Visual analogue 
scale, RTOG: Radiation therapy oncology group
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Rao et al. [76] in their single-blinded, randomized, controlled clinical 
trial compared turmeric gargle or povidone-iodine in head and neck 
cancer patients requiring 70 Gy of radiation or chemoradiotherapy 
(daily radiotherapy plus carboplatin once a week). They concluded that 
gargling with turmeric provided significant benefit by delaying and 
reducing the severity of mucositis.
CONCLUSION
Turmeric has been used in Ayurvedic medicine since ancient times, 
with various biological applications. Curcumin is a nontoxic, highly 
promising natural antioxidant compound having a wide spectrum of 
biological functions. It is expected that curcumin may find application 
as a novel drug in the near future to control various oral mucosal 
disorders. This paper reviewed the role of curcumin in tobacco-
associated and ulcerative conditions. Curcumin, therefore, fulfills two 
roles in the putative treatment of oral mucosal disorders, as an anti-
inflammatory agent, antioxidant, antimicrobial, and chemopreventive 
agent. It also provides the basis for a simple, safe, acceptable, and cost-
effective intervention for oral mucosal disorders.
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